Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study.

Introduction: Amivantamab, an EGFR-MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced non-small cell lung cancer (NSCLC) as monotherapy or combined with other agents. Intravenous amivantamab is associated with a 67% infusion-related reactions (IRR) rate.

Methods: The phase 2 SKIPPirr study (NCT05663866) enrolled patients with EGFR-mutated (Ex19del/L858R) advanced NSCLC after progression on osimertinib and platinum-based chemotherapy who received intravenous amivantamab plus oral lazertinib (amivantamab-lazertinib), a third-generation tyrosine kinase inhibitor.

Non-Intrusive Monitoring of Vital Signs in the Lower Limbs Using Optical Sensors.

Invisible health monitoring is currently a topic of global interest within the scientific community. Sensorization of everyday objects can provide valuable health information without requiring any changes in people's routines. In this work, a feasibility study of photoplethysmography (PPG) acquisition in the lower limbs for continuous and real-time monitoring of the vital signs, including heart rate (HR) and respiratory rate (RR), is presented.

TerraSAR-X SAR data for classification of ice-free areas and glacier facies on Fildes Peninsula, King George Island, Antarctica.

The region of the Maritime Antarctic suffers significantly from climate change, resulting in regional warming and consequently affecting coverage. This study characterized three surface zones of Collins Glacier and three other zones in ice-free areas on the Fildes Peninsula, which has an area of 29.6 km².

Understanding tinnitus symptom dynamics and clinical improvement through intensive longitudinal data.

Intensive longitudinal sampling enhances subjective data collection by capturing real-time, dynamic inputs in natural settings, complementing traditional methods. This study evaluates the feasibility of using daily self-reported app data to assess clinical improvement among tinnitus patients undergoing treatment. App data from a multi-center randomized clinical trial were analysed using time-series feature extraction and nested cross-validated ordinal regression with elastic net regulation to predict clinical improvement based on the Clinical Global Impression-Improvement scale (CGI-I).

The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma.

Glioblastoma (GBM) is a highly lethal type of cancer, frequently presenting an unfavorable prognosis. The current treatment options for this neoplasia are still limited, highlighting the need for further research evaluating new drugs to treat GBM or to serve as an adjuvant to improve the efficiency of currently used therapies. In this sense, the inhibition of A2A receptors in the brain has presented a neuroprotective role for several diseases, such as neurodegenerative conditions, and it has been suggested as a possible pharmacological target in some types of cancer; thus, it also can be underscored as a potential target in GBM.